ReviewFrontiers in immunology2026
Epigenetic reprogramming in autoimmune and immune-mediated skin disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune skin diseases exhibit chronicity and site-specific relapse that are not fully explained by genetic susceptibility or cytokine signaling alone. Emerging evidence suggests that epigenetic reprogramming of skin-resident immune cells contributes to disease persistence and recurrence. Methods: We conducted a structured narrative review of the human literature by searching PubMed for studies published from database inception through March 1, 2026. The literature search was performed between February 1 and March 1, 2026 and focused on epigenetic mechanisms across major autoimmune dermatoses, including DNA methylation, histone modification, chromatin accessibility, non-coding RNA regulation, and emerging single-cell and spatial epigenomic technologies. Results: Current evidence suggests stable chromatin remodeling in keratinocytes and immune cells, including tissue-resident memory T cells, that persists after clinical resolution and may facilitate rapid disease reactivation. Environmental exposures further reinforce these epigenetic programs, contributing to disease heterogeneity, chronicity, and site-specific relapse. Conclusion: Collectively, these findings are consistent with a model in which autoimmune skin diseases are maintained by maladaptive epigenetic memory. Although causal inference remains limited by the relative scarcity of cell-type-resolved human epigenomic data and the predominance of cross-sectional studies, this framework suggests that achieving durable therapeutic remission may require reprogramming pathogenic chromatin states rather than solely suppressing inflammatory pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.